Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kramer

Showing results (191-200 of 240) with videos related to

Pageof 24
Sort By:
Bone Marrow Transplantation|November 13, 2021
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Frontiers in Immunology|October 31, 2022
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-diseaseThomas Krüger, Rebekka Wehner, Maik Herbig, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Bone Marrow Transplantation|October 8, 2020
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trialMarkus Schaich, Stefani Parmentier, Michael Kramer, et al.
Nature Astronomy|July 26, 2022
Discovery of a radio emitting neutron star with an ultra-long spin period of 76 secondsManisha Caleb, Ian Heywood, Kaustubh Rajwade, et al.
The Journal of Clinical Investigation|September 13, 2022
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemiaSergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML IntergroupThomas Büchner, Richard F Schlenk, Markus Schaich, et al.
Pageof 24

Showing results (191-200 of 240) with videos related to

Sort By:
Pageof 24
Bone Marrow Transplantation|November 13, 2021
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Frontiers in Immunology|October 31, 2022
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-diseaseThomas Krüger, Rebekka Wehner, Maik Herbig, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Bone Marrow Transplantation|October 8, 2020
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Helmuth Schmidt, Gero Hütter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2015
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDAnthony D Ho, Johannes Schetelig, Tilmann Bochtler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trialMarkus Schaich, Stefani Parmentier, Michael Kramer, et al.
Nature Astronomy|July 26, 2022
Discovery of a radio emitting neutron star with an ultra-long spin period of 76 secondsManisha Caleb, Ian Heywood, Kaustubh Rajwade, et al.
The Journal of Clinical Investigation|September 13, 2022
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemiaSergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML IntergroupThomas Büchner, Richard F Schlenk, Markus Schaich, et al.
Pageof 24